Merck & Co. (MRK) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Merck & Co. · Health Care · ref. ETF XLV · 77 calls · price $141.98
What the company does: Merck & Co., Inc. operates as a healthcare company worldwide.
📈 Merck & Co. (MRK) stock price
$141.98+67.6% over range
Oct 14, 25low $82.49 · high $156.45Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
84% recommend buying · 19 analysts
📊 JPI status : Merck & Co. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 MRK price target & analyst consensus — price $142
The price target · all analysts combined (19 targets)
Highest target · 2 firms of 19$180+26.8%
Median target · of 19 targets$165+16.2%
Lowest target · 1 firm of 19$138-2.8%
Current price$141.98
Where these 19 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
1789%
$143 ↔ $180
Below
211%
$138 ↔ $141
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (240 calls tested). It aims for $170 (+20 %), call made on August 21, 2026, maturing on August 21, 2027 (54 d ago).
The 12 reliable analysts
$170+20 %
The 7 other firms
$145+2.1 %
How to read it: the 12 reliable firms are not filtered by optimism — 12 aim above the price, 0 below, hence their $170 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 19 ratings (last 6 months)
Strong Buy00%
Buy1684%
Hold316%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 MRK price target all
All 21 calls, one by one, with our verdict on each firm.
→ See all 21 targets, analyst by analyst💡 The best analysts on MRK most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in MRK? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Merck & Co.? The JPI assistant answers using our backtest data.
💰 Merck & Co. dividend: yield, history & growth › open the full page
2.68%annual yield
🏆 Aristocrat — 28 yrs of consecutive dividend increases
That's ~$3.36 per share per year.
📈 Merck & Co. fundamentals: valuation, margins & growth › open the full page
P/E 112.7Net margin 4.8 %Revenue growth +5.1 %Very high P/E
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 24 %
2023
Rev +1%Profit −97%
2024
Rev +7%Profit +4590%
2025
Rev +1%Profit +7%
🔎 Detailed analyses
✅ Historical analyst reliability on MRK
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Wells Fargo ↗ | 100% | +21.4% | 5 |
| Societe Generale | 100% | +18.9% | 2 |
| SunTrust Robinson Humphrey | 100% | +16.9% | 3 |
| Jefferies ↗ | 100% | +15.4% | 5 |
| Argus Research ↗ | 100% | +12.0% | 2 |
| Atlantic Equities | 100% | +9.9% | 5 |
| Deutsche Bank ↗ | 100% | +8.9% | 2 |
| MKM Partners | 100% | +7.5% | 2 |
| B of A Securities ↗ | 90% | +12.2% | 10 |
| Citigroup ↗ | 89% | +12.7% | 9 |
See the other 13 firms
| Cantor Fitzgerald ↗ | 31% | -16.4% | 26 |
| UBS ↗ | 38% | -3.4% | 13 |
| Morgan Stanley ↗ | 50% | +1.9% | 8 |
| Goldman Sachs ↗ | 50% | +10.4% | 2 |
| Truist Securities ↗ | 58% | -3.5% | 12 |
| Mizuho ↗ | 67% | +6.6% | 3 |
| Barclays ↗ | 67% | +7.1% | 18 |
| Guggenheim ↗ | 67% | +12.0% | 9 |
| Berenberg ↗ | 75% | +4.0% | 4 |
| Credit Suisse | 82% | +13.7% | 11 |
| SVB Leerink | 84% | +16.6% | 19 |
| JP Morgan ↗ | 86% | +12.9% | 7 |
| BMO Capital ↗ | 88% | +17.6% | 16 |
📊 What $1,000 invested in Merck & Co. would be worth › open the full page
In short — $1,000 invested in Merck & Co. 10 years ago would be worth $2,550 today, i.e. +10%/yr on average. Best year: 2022 (+45%), worst: 2020 (-10%). Price performance, excluding dividends.
If I'd invested $1,000 in Merck & Co.
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,292 | +29% |
| 3 years ago | $1,158 | +16% |
| 5 years ago | $1,646 | +65% |
Return by year (Merck & Co.)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +22% | $1,221 (+22%) |
| 2025 | +6% | $1,292 (+29%) |
| 2024 | -9% | $1,179 (+18%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Merck & Co.
Loading news…
📋 All analyst calls on MRK
Filtered on — · ✕ show all
■ Neutral neutral · not a buy · 🎯$145
Price at call : $141.98 — gap to target +2%
Today : $141.98 — gap to target +2%
🎯 on MRK : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Oct 12, 27
matures : Oct 12, 27
RBC Capital ↗
Oct 12, 26
■ Sector Perform neutral · not a buy · 🎯$145
Price at call : $141.98 — gap to target +2%
Today : $141.98 — gap to target +2%
🎯 on MRK : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Oct 12, 27
matures : Oct 12, 27
Cantor Fitzgerald ↗
Oct 8, 26
■ Neutral neutral · not a buy · 🎯$145
Price at call : $142.38 — gap to target +2%
Today : $141.98 — gap to target +2%
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
in progress (365j)
matures : Oct 8, 27
matures : Oct 8, 27
Morgan Stanley ↗
Oct 7, 26
▲ Overweight · 🎯$177
Price at call : $142.38 — upside +24%
Today : $141.98 — upside +25%
🎯 on MRK : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Oct 7, 27
matures : Oct 7, 27
▲ Overweight · 🎯$165
Price at call : $141.94 — upside +16%
Today : $141.98 — upside +16%
🎯 on MRK : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : Oct 5, 27
matures : Oct 5, 27
Scotiabank ↗
Sep 29, 26
▲ Sector Outperform · 🎯$180
Price at call : $145.31 — upside +24%
Today : $141.98 — upside +27%
🎯 on MRK : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Sep 29, 27
matures : Sep 29, 27
▲ Buy · 🎯$172
Price at call : $143.93 — upside +20%
Today : $141.98 — upside +21%
🎯 on MRK : no call matured yet · 📊 on Health : 55.2% · +1.7% (29 calls)
in progress (365j)
matures : Sep 10, 27
matures : Sep 10, 27
Leerink Partners ↗
Sep 9, 26
▲ Outperform · 🎯$161
Price at call : $144.71 — upside +11%
Today : $141.98 — upside +13%
🎯 on MRK : 100% (1 call matured) · 📊 on Health : 53.7% · -6.2% (41 calls)
in progress (365j)
matures : Sep 9, 27
matures : Sep 9, 27
See the other 69 calls, newest to oldest
Guggenheim ↗
Sep 8, 26
▲ Buy · 🎯$170
Price at call : $147.53 — upside +15%
Today : $141.98 — upside +20%
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
in progress (365j)
matures : Sep 8, 27
matures : Sep 8, 27
Wells Fargo ↗
Sep 4, 26
▲ Overweight · 🎯$170
Price at call : $148.46 — upside +15%
Today : $141.98 — upside +20%
🎯 on MRK : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Sep 4, 27
matures : Sep 4, 27
Wolfe Research ↗
Aug 25, 26
▲ Outperform · 🎯$180
Price at call : $153.1 — upside +18%
Today : $141.98 — upside +27%
🎯 on MRK : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Aug 25, 27
matures : Aug 25, 27
Argus Research ↗
Aug 25, 26
▲ Buy · 🎯$170
Price at call : $156.45 — upside +9%
Today : $141.98 — upside +20%
🎯 on MRK : no call matured yet · 📊 on Health : 55.3% · +2.1% (159 calls)
in progress (365j)
matures : Aug 25, 27
matures : Aug 25, 27
Goldman Sachs ↗
Aug 21, 26
▲ Buy · 🎯$160
Price at call : $150.66 — upside +6%
Today : $141.98 — upside +13%
🎯 on MRK : no call matured yet · 📊 on Health : 51.4% · +2.3% (243 calls)
in progress (365j)
matures : Aug 21, 27
matures : Aug 21, 27
BMO Capital ↗
Aug 20, 26
▲ Outperform · 🎯$170
Price at call : $152.55 — upside +11%
Today : $141.98 — upside +20%
🎯 on MRK : no call matured yet · 📊 on Health : 60.4% · +8.8% (240 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
▲ Buy · 🎯$175
Price at call : $152.55 — upside +15%
Today : $141.98 — upside +23%
🎯 on MRK : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
RBC Capital ↗
Aug 20, 26
■ Sector Perform neutral · not a buy · 🎯$150
Price at call : $148.99 — gap to target +1%
Today : $141.98 — gap to target +6%
🎯 on MRK : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
Morgan Stanley ↗
Aug 20, 26
▲ Overweight · 🎯$179
Price at call : $148.99 — upside +20%
Today : $141.98 — upside +26%
🎯 on MRK : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
Daiwa Capital ↗
Aug 12, 26
▲ Outperform · 🎯$143
Price at call : $135.55 — upside +5%
Today : $141.98 — upside +1%
🎯 on MRK : 100% (1 call matured) · 📊 on Health : 40% · -1.0% (5 calls)
in progress (365j)
matures : Aug 12, 27
matures : Aug 12, 27
Argus Research ↗
Aug 11, 26
▲ Buy · 🎯$145
Price at call : $130.42 — upside +11%
Today : $141.98 — upside +2%
🎯 on MRK : no call matured yet · 📊 on Health : 55.3% · +2.1% (159 calls)
in progress (365j)
matures : Aug 11, 27
matures : Aug 11, 27
Guggenheim ↗
Aug 5, 26
▲ Buy · 🎯$146
Price at call : $128.33 — upside +14%
Today : $141.98 — upside +3%
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
▲ Overweight · 🎯$150
Price at call : $130.36 — upside +15%
Today : $141.98 — upside +6%
🎯 on MRK : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
▲ Overweight · 🎯$140
Price at call : $120.78 — upside +16%
Today : $141.98 — upside -1%
🎯 on MRK : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
BMO Capital ↗
Jul 13, 26
▲ Outperform · 🎯$142
Price at call : $124.03 — upside +14%
Today : $141.98 — upside +0%
🎯 on MRK : no call matured yet · 📊 on Health : 60.4% · +8.8% (240 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
Guggenheim ↗
Jul 13, 26
▲ Buy · 🎯$145
Price at call : $124.03 — upside +17%
Today : $141.98 — upside +2%
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
Morgan Stanley ↗
Jul 9, 26
■ Equal-Weight neutral · not a buy · 🎯$113
Price at call : $123.54 — gap to target -9%
Today : $141.98 — gap to target -20%
🎯 on MRK : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Jul 9, 27
matures : Jul 9, 27
RBC Capital ↗
Jul 8, 26
▲ Outperform · 🎯$142
Price at call : $125.07 — upside +14%
Today : $141.98 — upside +0%
🎯 on MRK : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
Wells Fargo ↗
Jul 8, 26
▲ Overweight · 🎯$150
Price at call : $125.99 — upside +19%
Today : $141.98 — upside +6%
🎯 on MRK : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
Cantor Fitzgerald ↗
Jul 6, 26
■ Neutral neutral · not a buy · 🎯$120
Price at call : $126.78 — gap to target -5%
Today : $141.98 — gap to target -15%
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
B of A Securities ↗
Jun 30, 26
▲ Buy · 🎯$141
Price at call : $125.37 — upside +12%
Today : $141.98 — upside -1%
🎯 on MRK : no call matured yet · 📊 on Health : 48.1% · +2.0% (362 calls)
in progress (365j)
matures : Jun 30, 27
matures : Jun 30, 27
Scotiabank ↗
Jun 30, 26
▲ Sector Outperform · 🎯$155
Price at call : $125.37 — upside +24%
Today : $141.98 — upside +9%
🎯 on MRK : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Jun 30, 27
matures : Jun 30, 27
▲ Outperform · 🎯$138
Price at call : $125.45 — upside +10%
Today : $141.98 — upside -3%
🎯 on MRK : no call matured yet · 📊 overall : 88.9% · +31.3% (9 calls)
in progress (365j)
matures : Jun 24, 27
matures : Jun 24, 27
Wells Fargo ↗
May 1, 26
▲ Overweight · 🎯$145
Price at call : $113.11 — upside +28%
Today : $141.98 — upside +2%
🎯 on MRK : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
▲ Buy · 🎯$145
Price at call : $119.96 — upside +21%
Today : $141.98 — upside +2%
🎯 on MRK : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Apr 13, 27
matures : Apr 13, 27
▲ Overweight · 🎯$135
Price at call : $119.28 — upside +13%
Today : $141.98 — upside -5%
🎯 on MRK : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : Apr 6, 27
matures : Apr 6, 27
RBC Capital ↗
Mar 30, 26
▲ Outperform · 🎯$142
Price at call : $120.29 — upside +18%
Today : $141.98 — upside +0%
🎯 on MRK : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Mar 30, 27
matures : Mar 30, 27
■ Neutral neutral · not a buy · 🎯$125
Price at call : $115.68 — gap to target +8%
Today : $141.98 — gap to target -12%
🎯 on MRK : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Mar 20, 27
matures : Mar 20, 27
Wells Fargo ↗
Mar 12, 26
▲ Overweight · 🎯$150
Price at call : $115.91 — upside +29%
Today : $141.98 — upside +6%
🎯 on MRK : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Mar 12, 27
matures : Mar 12, 27
RBC Capital ↗
Feb 25, 26
▲ Outperform · 🎯$142
Price at call : $122.46 — upside +16%
Today : $141.98 — upside +0%
🎯 on MRK : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Feb 25, 27
matures : Feb 25, 27
▲ Overweight · 🎯$140
Price at call : $123.82 — upside +13%
Today : $141.98 — upside -1%
🎯 on MRK : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
Freedom Broker
Feb 9, 26
■ Hold neutral · not a buy · 🎯$110
Price at call : $117.65 — gap to target -7%
Today : $141.98 — gap to target -23%
🎯 on MRK : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
Guggenheim ↗
Feb 6, 26
▲ Buy · 🎯$140
Price at call : $117.65 — upside +19%
Today : $141.98 — upside -1%
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
in progress (365j)
matures : Feb 6, 27
matures : Feb 6, 27
■ Neutral neutral · not a buy · 🎯$120
Price at call : $119.75 — gap to target +0%
Today : $141.98 — gap to target -15%
🎯 on MRK : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
Cantor Fitzgerald ↗
Feb 4, 26
■ Neutral neutral · not a buy · 🎯$120
Price at call : $119.75 — gap to target +0%
Today : $141.98 — gap to target -15%
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
Wells Fargo ↗
Feb 4, 26
▲ Overweight · 🎯$135
Price at call : $119.75 — upside +13%
Today : $141.98 — upside -5%
🎯 on MRK : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
■ Neutral neutral · not a buy · 🎯$115
Price at call : $106.9 — gap to target +8%
Today : $141.98 — gap to target -19%
🎯 on MRK : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
■ Hold neutral · not a buy · 🎯$120
Price at call : $111.11 — gap to target +8%
Today : $141.98 — gap to target -15%
🎯 on MRK : no call matured yet · 📊 on Health : 48% · +0.6% (98 calls)
in progress (365j)
matures : Jan 20, 27
matures : Jan 20, 27
Wolfe Research ↗
Jan 8, 26
▲ Outperform · 🎯$135
Price at call : $110.99 — upside +22%
Today : $141.98 — upside -5%
🎯 on MRK : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Jan 8, 27
matures : Jan 8, 27
▲ Buy · 🎯$130
Price at call : $110.99 — upside +17%
Today : $141.98 — upside -8%
🎯 on MRK : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Jan 7, 27
matures : Jan 7, 27
■ Neutral neutral · not a buy · 🎯$110
Price at call : $110.99 — gap to target -1%
Today : $141.98 — gap to target -23%
🎯 on MRK : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Jan 7, 27
matures : Jan 7, 27
BMO Capital ↗
Dec 18, 25
▲ Outperform · 🎯$130
Price at call : $100.69 — upside +29%
Today : $141.98 — upside -8%
🎯 on MRK : no call matured yet · 📊 on Health : 60.4% · +8.8% (240 calls)
in progress (365j)
matures : Dec 18, 26
matures : Dec 18, 26
■ Hold neutral · not a buy · 🎯$90
Price at call : $81.14 — gap to target +11%
Today : $141.98 — gap to target -37%
🎯 on MRK : 67% (3 calls matureds) · 📊 on Health : 40% · +2.8% (20 calls)
in progress (365j)
matures : Sep 17, 26
matures : Sep 17, 26
Guggenheim ↗
Apr 17, 25
▲ Buy · 🎯$115
Price at call : $77.85 — upside +48%
Today : $141.98 — upside -19%
Expected +48% · Actual +50% · Reason (≥ +15%) : ✓ Yes
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
+50.4%
stock +50% · XLV +11%
matured Apr 17, 26
Guggenheim ↗
Feb 12, 25
▲ Buy · 🎯$115
Price at call : $84.42 — upside +36%
Today : $141.98 — upside -19%
Expected +36% · Actual +44% · Reason (≥ +15%) : ✓ Yes
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
+43.8%
stock +44% · XLV +8%
matured Feb 12, 26
Guggenheim ↗
Jan 17, 25
▲ Buy · 🎯$122
Price at call : $97.92 — upside +25%
Today : $141.98 — upside -14%
Expected +25% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
+11.8%
stock +12% · XLV +11%
matured Jan 17, 26
Leerink Partners ↗
Jan 13, 25
▲ Outperform · 🎯$119
Price at call : $99.65 — upside +19%
Today : $141.98 — upside -16%
Expected +19% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 100% (1 call matured) · 📊 on Health : 53.7% · -6.2% (41 calls)
+11.4%
stock +11% · XLV +13%
matured Jan 13, 26
Guggenheim ↗
Nov 6, 24
▲ Buy · 🎯$130
Price at call : $101.17 — upside +28%
Today : $141.98 — upside -8%
Expected +28% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
-14.7%
stock -15% · XLV -2%
matured Nov 6, 25
Cantor Fitzgerald ↗
Oct 3, 24
▲ Overweight · 🎯$155
Price at call : $109.77 — upside +41%
Today : $141.98 — upside +9%
Expected +41% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-19.1%
stock -19% · XLV -5%
matured Oct 3, 25
Cantor Fitzgerald ↗
Sep 16, 24
▲ Overweight · 🎯$155
Price at call : $118.29 — upside +31%
Today : $141.98 — upside +9%
Expected +31% · Actual -31% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-31.4%
stock -31% · XLV -12%
matured Sep 16, 25
Cantor Fitzgerald ↗
Aug 29, 24
▲ Overweight · 🎯$155
Price at call : $118.45 — upside +31%
Today : $141.98 — upside +9%
Expected +31% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-27.8%
stock -28% · XLV -12%
matured Aug 29, 25
Cantor Fitzgerald ↗
Jun 20, 24
▲ Overweight · 🎯$155
Price at call : $130.72 — upside +19%
Today : $141.98 — upside +9%
Expected +19% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-38.7%
stock -39% · XLV -10%
matured Jun 20, 25
Cantor Fitzgerald ↗
Jun 18, 24
▲ Overweight · 🎯$155
Price at call : $127.99 — upside +21%
Today : $141.98 — upside +9%
Expected +21% · Actual -38% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-38.0%
stock -38% · XLV -9%
matured Jun 18, 25
Cantor Fitzgerald ↗
Jun 4, 24
▲ Overweight · 🎯$155
Price at call : $129.45 — upside +20%
Today : $141.98 — upside +9%
Expected +20% · Actual -40% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-40.0%
stock -40% · XLV -9%
matured Jun 4, 25
Cantor Fitzgerald ↗
Apr 18, 24
▲ Overweight · 🎯$135
Price at call : $125.78 — upside +7%
Today : $141.98 — upside -5%
Expected +7% · Actual -38% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-38.1%
stock -38% · XLV -5%
matured Apr 18, 25
▲ Buy · 🎯$143
Price at call : $126.56 — upside +13%
Today : $141.98 — upside +1%
Expected +13% · Actual -38% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (3 calls matureds) · 📊 on Health : 40% · +2.8% (20 calls)
-37.6%
stock -38% · XLV -7%
matured Apr 8, 25
Cantor Fitzgerald ↗
Apr 5, 24
▲ Overweight · 🎯$135
Price at call : $127.99 — upside +5%
Today : $141.98 — upside -5%
Expected +5% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-36.6%
stock -37% · XLV -6%
matured Apr 5, 25
Cantor Fitzgerald ↗
Apr 1, 24
▲ Overweight · 🎯$135
Price at call : $130.99 — upside +3%
Today : $141.98 — upside -5%
Expected +3% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-33.5%
stock -33% · XLV -2%
matured Apr 1, 25
Cantor Fitzgerald ↗
Mar 27, 24
▲ Overweight · 🎯$135
Price at call : $131.75 — upside +2%
Today : $141.98 — upside -5%
Expected +2% · Actual -34% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-33.5%
stock -34% · XLV -2%
matured Mar 27, 25
Cantor Fitzgerald ↗
Mar 11, 24
▲ Overweight · 🎯$135
Price at call : $122.77 — upside +10%
Today : $141.98 — upside -5%
Expected +10% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-22.8%
stock -23% · XLV -0%
matured Mar 11, 25
Cantor Fitzgerald ↗
Feb 29, 24
▲ Overweight · 🎯$135
Price at call : $126.96 — upside +6%
Today : $141.98 — upside -5%
Expected +6% · Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 0% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-26.6%
stock -27% · XLV +2%
matured Feb 28, 25
Guggenheim ↗
Apr 11, 23
▲ Buy · 🎯$124
Price at call : $113.75 — upside +9%
Today : $141.98 — upside -13%
Expected +9% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
+10.9%
stock +11% · XLV +5%
matured Apr 10, 24
▲ Buy · 🎯$130
Price at call : $107.69 — upside +21%
Today : $141.98 — upside -8%
Expected +21% · Actual +14% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (3 calls matureds) · 📊 on Health : 40% · +2.8% (20 calls)
+14.0%
stock +14% · XLV +18%
matured Mar 9, 24
Guggenheim ↗
Nov 1, 22
▲ Buy · 🎯$111
Price at call : $99.4 — upside +12%
Today : $141.98 — upside -22%
Expected +12% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
+3.5%
stock +3% · XLV -3%
matured Nov 1, 23
Guggenheim ↗
Oct 10, 22
▲ Buy
Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
+14.5%
stock +15% · XLV +8%
matured Oct 10, 23
▲ Buy · 🎯$100
Price at call : $86.95 — upside +15%
Today : $141.98 — upside -30%
Expected +15% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on MRK : 67% (3 calls matureds) · 📊 on Health : 40% · +2.8% (20 calls)
+24.5%
stock +24% · XLV +5%
matured Sep 14, 23
Daiwa Capital ↗
Jul 7, 22
▲ Outperform · 🎯$102
Price at call : $93.01 — upside +10%
Today : $141.98 — upside -28%
Expected +10% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on MRK : 100% (1 call matured) · 📊 on Health : 40% · -1.0% (5 calls)
+17.2%
stock +17% · XLV -1%
matured Jul 7, 23
Guggenheim ↗
Apr 29, 20
▲ Buy · 🎯$93
Price at call : $75.71 — upside +23%
Today : $141.98 — upside -34%
Expected +23% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
-6.1%
stock -6% · XLV +22%
matured Apr 29, 21
Guggenheim ↗
Jan 12, 17
▲ Buy · 🎯$70
Price at call : $59.36 — upside +18%
Today : $141.98 — upside -51%
Expected +18% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on MRK : 67% (9 calls matureds) · 📊 on Health : 55.4% · +4.9% (101 calls)
-5.7%
stock -6% · XLV +23%
matured Jan 12, 18
Frequently asked questions
Should I buy Merck & Co. stock?
This isn't buy advice. For Merck & Co., the analyst consensus is "Buy", with an average price target of $165 (+16% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (5 calls tracked on Merck & Co.). We show the numbers — you decide.
Is it too late to buy Merck & Co.? How high can it go?
The most bullish analyst target on Merck & Co. is $180 (+27% above today's price); the average is $165. That's the upside they see. Check how reliable those analysts have actually been on Merck & Co. on our site before trusting it.
Is Merck & Co. still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 23 analysts have a real record on Merck & Co., the best hitting 100% over 5 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in Merck & Co.? The case for and against
The arguments for and against, one by one, from the numbers: why invest in MRK (and why hesitate).
What has Merck & Co.'s past performance been?
Historical returns and a "how much if I had invested" calculator: MRK performance & returns.
Does Merck & Co. pay a dividend?
Yield, consistency and growth history of the dividend: MRK's dividend.
What is the best month to buy MRK?
The 12 months ranked by the stock's past returns: best & worst month to buy MRK.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX